Skip to main content

UC Davis Comprehensive Cancer Center

Marcio H. Malogolowkin, M.D. View profile as PDF

Marcio H. Malogolowkin

Philosophy of Care

We MUST treat our patients and families as we wish that our own kids and families would be treated. 


Clinical Interests

Pediatric Solid tumors, Developmental Therapeutics Adolescent and Young Adults Cancer.


Research/Academic Interests

Pediatric Solid tumors, Developmental Therapeutics Adolescent and Young Adults Cancer

Title:

Chief, Division of Hematology Oncology
Professor, Department of Pediatrics

Specialty:

Pediatric Hematology/Oncology

Division:

Pediatric Hematology/Oncology

Address/Phone:

UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Driving Directions
Phone: 916-734-5959
Phone: 800-800--362-5566

Additional Phone:

Phone: 916-734-2781
Clinic Fax: 916-451-3014
Department Referral Phone: 916-734-2782
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Other Languages:

Portuguese, Spanish

Education:

M.D., Federal University of Rio de Janeiro Medical School, Rio de Janeiro, Brazil 1982

Internships:

Pediatrics Hematology Oncology, Children's Hospital of Los Angeles, Los Angeles CA 1990-1991
Federal University of Rio de Janeiro Medical School, Rio de Janeiro, Brazil 1982

Residency:

Pediatrics, Children's Hospital of Los Angeles, Los Angeles CA 1991-1994

Fellowships:

Pediatrics Hematology Oncology, Children's Hospital of Los Angeles, Los Angeles, CA 1986-1989

Board Certifications:

American Board of Pediatrics, 1998
American Board of Pediatrics, Pediatric Hematology-Oncology, 1998

Professional Memberships:

American Society of Clinical Oncology
American Society of Pediatric Hematology/Oncology
Brazilian Society of Pediatric Hematology-Oncology
Sociedad Latino Americana de Oncologia-Pediatrica

Select Honors and Awards:

Morris & Mary Press Humanism Award, Children's Hospital Los Angeles, 2005

Best Doctors in America, 2008

Top Doctors, Pasadena Magazine, 2010

Super Doctors, Los Angeles Magazine, 2010

Best Doctors in America (r), Milwaukee-Racine-Kenosha Metro Area, 2011

Select Recent Publications:

Venkatramani R, Stein JE, Sapra A, Genyk Y, Jhaveri V, Malogolowkin M, Mascarenhas L, Effect of neoadjuvant chemotherapy on resectability of stage III and IV hepatoblastoma, British Journal of Surgery 2015 Jan;102(1):108-13.

Venkatramani R, Spector LG, Georgieff M, Tomlinson G, Krailo M, Malogolowkin M, Kohlmann W, Curtin K, Fonstad RK, Schiffman JD Congenital abnormalities and hepatoblastoma: A report from the Children's Oncology Group (COG) and the Utah Population Database (UPDB). Am J Med Genet A. 2014 Jun 16;164A(9):220-5.

Gonzalez-Morkos B, Zavala O, Malogolowkin M, Kuperberg A The Teen Impact Experience: A Webcast Pilot Project for Teens With Cancer and Blood Diseases. J Pediatr Oncol Nurs. 2014 Sep-Oct;31(5):272-6.

Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, Malogolowkin MH, Pashankar F, Villaluna D, Krailo M, Egler RA, Rodriguez-Galindo C, Frazier AL Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group. J Clin Oncol. 2014 Feb;10,32(5):465-470.

Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH, Meyers RL Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 2014 Feb;26(1):19-28.

Green DM, Breslow NE, D'Angio GJ, Malogolowkin MH, Ritchey ML, Evans AE, Beckwith JB, Perlman EJ, Shamberger RC, Peterson S, Grundy PE, Dome JS, Thomas PR, Kalapurakal JA Outcome of patients with stage II/favorable histology wilms tumor with and without local tumor spill: A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer. 2014 Jan;61(1):134-139.

López-Terrada D, Alaggio R, de Dávila MT, Czauderna P, Hiyama E, Katzenstein H, Leuschner I, Malogolowkin M, Meyers R, Ranganathan S, Tanaka Y, Tomlinson G, Fabrè M, Zimmermann A, Finegold MJ Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol. 2014 Mar;27(3):472-491.

Turcotte L, Georgieff M,Ross J, Feusner, J, Tomlinson G, Malogolowkin M, Krailo M, Miller N, Fonstad R, Spector L Neonatal Medical Exposures and Characteristics of Low Birth Weight Hepatoblastoma Cases: A Report From the Children’s Oncology Group Pediatr Blood Cancer 2014 Nov;61(11):2018-23.

Czauderna P, Beate H, Hiyama E, Krailo M, Maibach R, Rinaldi E, Aronson D, Malogolowkin M, Yoshimura K, Leuschner I, Lopez-Terrada D, Hishiki T, Perilongo G, Rangaswami A, von Schweinitz D, Schmid I, Watanabe K, Derosa M, Meyers R; Children's Hepatic tumors International Collaboration (CHIC) as a model of international global cooperation and clinical research in pediatric rare tumors. The Lancet [accepted for publication]2013.

Venkatramani R, Malogolowkin MH, Mascarenhas L Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatr Blood Cancer. 2014 Apr;61(4):756-759.

To see if Marcio H. Malogolowkin is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).